Drug Trial Radar · NCT04392154
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,153
Actual
Start
Jun 15, 2020
Primary completion
Jul 19, 2024
Study completion Apr 22, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Dermira, Inc.
- First posted
- May 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Conditions
- Atopic Dermatitis
Interventions
LebrikizumabBiological
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse EventsTime frame: Baseline to Week 100
Locations
321 sites in 16 countries. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
Clinical Research Center of Alabama- Birmingham
Birmingham, Alabama
Investigate MD
Scottsdale, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Burke Pharmaceutical Research
Hot Springs, Arkansas
Arkansas Research Trials
North Little Rock, Arkansas
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas
Orange County Research Institute
Anaheim, California
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California
Wallace Medical Group, Inc.
Beverly Hills, California
Hope Clinical Research, Inc.
Canoga Park, California
California Dermatology & Clinical Research Institute
Encinitas, California
First OC Dermatology
Fountain Valley, California
MD Studies
Fountain Valley, California
Center For Dermatology Clinical Research, Inc.
Fremont, California
Axon Clinical Research
Inglewood, California
Sunwise Clinical Research
Lafayette, California
Avance Clinical Trials Inc
Laguna Niguel, California
California Allergy and Asthma Medical Group + Research Center
Los Angeles, California
Keck School of Medicine University of Southern California
Los Angeles, California
Dermatology Research Associates
Los Angeles, California
LA Universal Research Center, INC
Los Angeles, California
Ablon Skin Institute and Research Center
Manhattan Beach, California
Dermatology Clinical Trials
Newport Beach, California
Cura Clinical Research
Palmdale, California
MD Strategies Research Centers MDSRC
Poway, California
Integrative Skin Science and Research
Sacramento, California
Integrative Skin Science and Research
Sacramento, California
Therapeutics Clinical Research
San Diego, California
University Clinical Trials
San Diego, California
University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology
San Diego, California
Synergy Dermatology
San Francisco, California
Care Access Research
San Jose, California
San Luis Dermatology & Laser Clinic
San Luis Obispo, California
Southern California Dermatology, Inc.
Santa Ana, California
IMMUNOe International Research Centers
Centennial, Colorado
Asthma and Allergy Associates, PC
Colorado Springs, Colorado
Central Connecticut Dermatology
Cromwell, Connecticut
Medical Faculty Associates, Inc.
Washington D.C., District of Columbia
George Washington University Medical Center
Washington D.C., District of Columbia
Showing 40 of 321 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.